Clinical trials: Inoperable
Thymoma
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
This study will investigate the efficacy of treatment with octroetide in patients with primary inoperable thymoma to reduce tumor size.
- Trial name
- NCT00332969
- Testing
- Octreotide
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
This first-in-human study evaluates safety, tolerability and distribution of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab in patients with FGFR3-expressing solid tumors.
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations
- Trial name
- NCT05363605
- Testing
- [225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
- Where
- 6 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 224 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Metastatic Epidural Spinal Cord Compression
Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression
The goal of this clinical study is to learn the feasibility of using a single session of radiation, known as spine stereotactic radiosurgery (SSRS), to treat metastatic epidural spinal cord compression.
- Trial name
- NCT01256554
- Testing
- Stereotactic Radiosurgery (SSRS), Questionnaires
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Tract Carcinoma
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
The purpose of this study is to evaluate the efficacy of gemcitabine and cisplatin in Korean patients with biliary tract (bile tracts of the gallbladder or liver) cancer.
- Trial name
- NCT00490399
- Testing
- gemcitabine, cisplatin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
This is a observational study in a real-world setting, not requiring determining a dosage regimen, dose reduction criteria, rest period criteria and withdrawal criteria.
- Trial name
- E-SPEC (NCT02551263)
- Testing
- Eribulin
- Where
- 2 sites in Japan
- Volunteers
- 201 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with…
- Trial name
- NCT02394548
- Testing
- Contralateral Esophageal Sparing Technique (CEST)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Renal Cancer, Renal Secondary Cancer
Stereotactic Body RadioTherapy With Continuous Tracking for Primary and Secondary Renal Cancer
This is a prospective, interventional, monocentric, clinical study of Stereotactic Body Radiation Therapy (SBRT) for primary or secondary renal tumors, delivering from 25-26 Gy/1 fraction to 42-48 Gy/3-4 fractions or 40-50 Gy/5…
- Conditions
- Renal Cancer, Renal Secondary Cancer, Stereotactic Body Radiotherapy
- Trial name
- SBRTRC (NCT07285538)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Squamous Cell Carcinoma of the Anus
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease.
- Trial name
- InterAACT (NCT02051868)
- Testing
- Cisplatin, 5-Fluorouracil (5-FU), Carboplatin
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- Royal Marsden NHS Foundation Trust
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Stage III Non-small Cell Lung Cancer
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
This is a pilot phase II study of histology based consolidation chemotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer (NSCLC) following concurrent chemo-radiotherapy.
- Trial name
- NCT01336543
- Testing
- Chemotherapy following concurrent Chemoradiotherapy
- Where
- United States
- Sponsor
- Syed Jafri
Breast Cancer
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
This is a clinical trial with a molecularly stratified parallel cohort, single arm design to explore the efficacy and safety of BKM120 in combination with tamoxifen in patients with ER/PR-positive, HER2-negative breast cancer…
- Trial name
- PIKTAM (NCT02404844)
- Testing
- BKM120, Tamoxifen
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- University Hospital, Essen
Pancreatic Neoplasms
Combination With Gemcitabine in Advanced Pancreatic Cancer
Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer.
- Trial name
- BAGPAC (NCT01251640)
- Testing
- BAY86-9766+Gemcitabine
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- Bayer
Inoperable Early Stage Non-small Cell Lung Cancer
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC).
- Trial name
- PEARL-2 (NCT01138748)
- Testing
- hypofractionated radiation therapy
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Neurofibromatosis Type I, Plexiform Neurofibroma
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Background: Patients with neurofibromatosis type 1 are at increased risk of developing tumors called plexiform neurofibromas (PN) that arise from nerves.
- Trial name
- NCT00727233
- Testing
- Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Dynamic Contrast Enhanced HCC SABR Liver Study
The high dose per fraction (>10Gy/fraction) used in Stereotactic Ablative Body Radiotherapy (SABR) has been shown to be more effective at local tumor control than treatments employing more conventional dose fractions.
- Trial name
- NCT02847767
- Testing
- Perfusion Imaging
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Malignant Intestinal Obstruction
Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients
The primary objective of this study is to assess the efficacy of Lanreotide 120 mg for the relief of clinical symptoms due to malignant bowel obstruction in inoperable patients.
- Trial name
- NCT01076803
- Testing
- Lanreotide (acetate)
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Non-small Cell Lung Cancer
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.
- Trial name
- NCT00643318
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States, China
- Volunteers
- 40 people
- Sponsor
- Accuray Incorporated
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition, Inoperable
- Trial name
- NCT05833594
- Testing
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital